



European Federation of Pharmaceutical
Industries and Associations



EFPIA Japan



- * We aim to provide Japanese patients with better access to innovative therapies; achieve appropriate reward for innovation; pursue a better balance between prevention and treatment; make Japan a more dynamic and attractive place to invest in for pharmaceutical companies; and further enhance the credibility of the pharmaceutical industry.



Message from the Chairman of the European Federation of Pharmaceutical Industries and Associations, Japan (EFPIA Japan)

Established in April 2002, EFPIA Japan represents 25 R&D-based European pharmaceutical companies operating in Japan. In 2014, combined sales from member companies accounted for over one-quarter of the pharmaceutical market in Japan. Our member companies are active in research and development, and have generated nearly one-third of all new drugs in Japan in the past three years from 2012 to 2014. We firmly believe that we form an important and indispensable part of the Japanese pharmaceutical

industry in terms of both sales and R&D of ethical pharmaceuticals.

We all recognize that our global and local healthcare environment is undergoing drastic changes. In this era of economic instability and reform, EFPIA Japan will engage in constructive dialogue with stakeholders in order to address current issues and find solutions that will support a healthcare system able to meet the challenge of an ageing population. Our mission is to contribute to the welfare of the Japanese population through the provision of innovative pharmaceuticals and vaccines without delay. We will pursue our goal of providing global best practices within Japan and aim to achieve the three key objectives below for improving the Japanese healthcare environment:

- **First, we need to maintain the new pricing system introduced in 2010. The system supports innovation, and has already contributed to improving Japan's standing in global drug development.**
- **Second, we should look to expedite Japanese patient access to global innovation by supporting the new pricing system mentioned above.**
- **Third, we should pursue a better balance between prevention and treatment to ensure improvement of public health.**

Improved access to medicines and vaccines will make Japan a more attractive place for investment by pharmaceutical companies.

EFPIA Japan has contributed greatly to improving the quality of life over the last 50 years. In addition to protecting lives, the industry supports the Japanese economy through financial investment and the employment of skilled workers, even during economic downturns. As responsible corporate citizens, we will develop an even stronger culture of compliance with the relevant rules and regulations, through which we will further contribute to the Japanese economy.

By always focusing on the patient first, we hope to strengthen our dialogue with decision makers to improve Japanese healthcare.

The direction, proposals and vision of EFPIA Japan are determined through the activities of six Committees (Pricing & Economics Committee, Technical Committee, Corporate Ethics Committee, Intellectual Property and Legal Committee, Biologics Committee, and Public Relations Committee).


We hope this brochure will help you understand more about EFPIA's activities and objectives in Japan. We also offer our sincere thanks for your interest in EFPIA Japan.

Carsten Brunn
EFPIA Japan Chairman

Board Members

Chairman:	Carsten Brunn	(Bayer Yakuhin, Ltd.)
Vice Chairman:	Gabriel Baertschi	(AstraZeneca K.K.)
Vice Chairman:	Philippe Fauchet	(GlaxoSmithKline K.K.)
Board of Director:	Stefan Sakurai	(LEO Pharma K.K.)
Board of Director:	Leo Lee	(Merck Serono Co., Ltd.)
Board of Director:	Masao Torii	(Nippon Boehringer Ingelheim Co., Ltd.)
Board of Director:	Dirk Kosche	(Novartis Pharma K.K.)
Board of Director:	Ole Molskov Beck	(Novo Nordisk Pharma Ltd.)
Board of Director:	Fabrice Baschiera	(Sanofi K.K.)
Director General:	Simon Collier	(EFPIA Japan)

Organization



EFPIA Japan Member Companies (Total 25 Companies)

- * Actelion Pharmaceuticals Japan Ltd.
- * AstraZeneca K.K.
- * Baxalta Japan Limited
- * Bayer Yakuhin, Ltd.
- * Bracco-Eisai Co., Ltd.
- * CHUGAI PHARMACEUTICAL CO., LTD.
- * CSL Behring K.K.
- * Ferring Pharmaceuticals Co., Ltd.
- * GALDERMA K.K.
- * GE Healthcare Japan Corporation
- * GlaxoSmithKline K.K.
- * Guerbet Japan KK
- * Ipsen Pharma Japan Representative Office
- * JANSSEN PHARMACEUTICAL K.K.
- * LEO Pharma K.K.
- * Lundbeck Japan K.K.
- * Merck Serono Co., Ltd.
- * Mylan EPD G.K.
- * NIHON SERVIER COMPANY LIMITED
- * Nippon Boehringer Ingelheim Co., Ltd.
- * Novartis Pharma K.K.
- * Novo Nordisk Pharma Ltd.
- * Sanofi K.K.
- * Shire Japan K.K.
- * UCB Japan Co., Ltd.

Committees

The mission of **the Pricing & Economics Committee**, or PEC, is to participate in discussions on a wide range of economic issues relating to the pharmaceutical business especially in regards to establishing a better pricing and a better healthcare system. To achieve this goal, the PEC actively engages in talks on healthcare system reform with the Japanese government, other industrial associations, and related stakeholders on behalf of European pharmaceutical companies in Japan.

Mission

Contribute to reform of the NHI drug price system through evidence-based proposals

Help ensure that the drug pricing system appropriately rewards innovation and provides incentives for investment

The Access Committee examines broad trends related to Market Access and the Health Technology Assessments (HTA) in Japan. Its primary goal is to ensure that HTA guidelines are formulated and implemented in a manner that values innovation and promotes greater patient access. The Access Committee wishes to ensure that global best practices related to HTA are understood by policymakers and adopted in Japan. These best practices include a transparent HTA review process, a robust dialogue between industry and government, and a health care system that continues to encourage the rapid introduction of safe and effective medicines for patients. The Committee develops materials for external stakeholders and meets with policymakers to explain the EFPIA positions on HTA and other market access issues, including the 14 Day Rule.




The Technical Committee works to improve the regulations as well as development and evaluation techniques that affect the innovative pharmaceutical industry and the implementation of those regulations. The aim is to ensure the rapid access by Japanese patients to safe and effective treatments.

Contributions to the development (clinical trials) environment: The Clinical Subcommittee regularly conducts investigations of the clinical trials environment in order to confirm changes in the environment and make recommendations based upon those changes. The Anti-cancer Drug Subcommittee makes proposals focused on the environment for implementing clinical trials of anti-cancer drugs, while also working in coordination with governmental and academic parties to participate in and make contributions through the "forum for the development of medicines to combat malignant tumors" which discusses various issues in the development of anti-cancer drugs.

Contributions to the regulatory affairs environment: Each subcommittee and task force is involved in investigating problem points and conducting interviews to gather opinions and requests regarding related regulations, guidelines and Q&As, as well as newly issued proposals in connection to the above, so as to resolve or make recommendations regarding such matters. The Product Quality subcommittee facilitates the appropriate and efficient implementation of submission and review of new drugs developed outside Japan and LCM of approved drugs manufactured outside Japan.

Contributions to technology: The Safety/PMS Subcommittee contributes to improvements in systems for monitoring the safety of Japanese pharmaceuticals through projects involving the participation of regulatory authorities and other pharmaceutical industry groups. The Pharmacokinetics/Pharmacodynamics Task Force (PK/PD TF) contributes to advance global development through activities including cooperation in Ministry of Health, Labour and Welfare-led investigations into differences between different ethnic groups. The Non-clinical Sub-committee contributes to improved evaluations based on the sharing of information, the organization of study meetings, and cooperation in the Pharmaceutical Evaluation Forum.




The Biologics Committee engages in a wide range of activities, covering treatments that have already been commercialized such as protein-preparations and antibody-based medicines created using genetic recombinants and other techniques, treatments based on next-generation medical technology that can hopefully be commercialized in the future such as products for regenerative medicine as well as nucleic acid-based pharmaceuticals, blood products including blood-related genetically-modified products, and vaccines. Three subcommittees, divided according to product group, are engaged in the following activities in order to improve the technical and regulatory environment for development, manufacturing, supply and safety monitoring.

Blood Product Subcommittee (BPSC): BPSC aims to establish a stable supply process for “Plasma Derived Products” manufactured from human blood and for essential products in medical care, and for any plasma related recombinant products that are manufactured with the world’s most advanced technology. With an eye to the future, the BPSC is also pursuing recommendations and dialogues with the Japanese Government to solve issues such as a lack of blood donors, and a production and supply process for plasma derived products during both normal times and emergencies.

Vaccine Subcommittee: In recent years, innovative overseas vaccines have been approved and come into use in Japan, and a considerable improvement has been achieved in the vaccine gap versus overseas countries. However, many areas still require work, including certain systemic issues such as the continued inability to use certain pediatric vaccines in Japan as well as low rates of vaccination. The subcommittee makes proposals to resolve these issues and works to provide good vaccines more promptly and more broadly in Japanese clinical settings.

Biological Products Subcommittee: Biological products are diverse but hold out great hope of new and innovative treatments. Among important issues are the future positioning of biosimilars as well as regenerative treatments including genetic treatment. The subcommittee harnesses the experience and track record of EFPIA in Europe in order to evaluate various different issues and produce recommendations.



Governance Legal Committee,

newly established by the merger of Corporate Ethics Committee and Intellectual Property and Legal Committee, covers legal, ethics and compliance area of business in which member firms are required to be adaptive to changes in business environment. Governance Legal Committee keeps its predecessors as two working groups (WG).

Corporate Ethics WG: Makes proposals to enable member firms to conduct business in compliance with a proper level of ethics and compliance standard. Facilitates compliance workshops where member firms can exchange its opinions on ethics and compliance in the pharmaceutical industry. On behalf of EFPIA Japan, closely and proactively working with Japan Pharmaceutical Manufacturers Association and other healthcare industry associations, promotes a level of business compliance in the pharmaceutical industry in Japan.

Intellectual Property and Legal WG: Investigates and studies the latest legislations, regulations and IP strategies in the healthcare industry in Europe as well as Japan. Exchanges opinions with member firms and industry associations, and makes proposals relating to Intellectual Property and legal matters. Contributes to the advancement of healthcare industry legislations and regulations in Japan.

The Public Relations Committee

works to inform healthcare stakeholders, including patients, the general public, medical professionals and policy-makers, of the positions and activities of the European pharmaceutical industry as well as EFPIA Japan. The committee holds press conferences, issues press releases and organizes media seminars in order to ensure that the appropriate information is shared with the media, and ultimately with the relevant stakeholders.



Innovative Medicines Initiative (IMI)


The Innovative Medicines Initiative (IMI), established in 2008 by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Commission, is one of the world's largest public-private partnerships. IMI has established its position as the pioneer for open collaboration which dramatically changes the way pharmaceutical research and development is carried out.

By the end of 2014, IMI had implemented more than 60 projects and consortiums with the aim of increasing the efficiency of pharmaceutical research and development and improving processes in order to deliver safer, more effective pharmaceuticals to patients. Themes addressed cover a wide range of issues that form bottlenecks in drug discovery including searching for biomarkers related to pharmaceutical safety and efficacy, pre-clinical development, research into pharmacokinetics and pharmacodynamics, pharmaceutical formulation development, database construction, and the development of educational programs.

The success of IMI is determined by collaborations. More than 7,000 researchers affiliated with academic institutions, pharmaceutical companies, small and medium-sized enterprises, patient organizations and regulatory authorities from Europe and around the world participate in the IMI projects. IMI's total budget is €5 billion, with half the budget coming from the EU's research program and the other half of the budget coming from EFPIA's member companies.

In recent years, progress is being made in public-private sector collaboration in the creation of systems for research and development in Japan. EFPIA Japan works to share the European experience of partnership.

Partnership



IMI project examples

NEWMEDS: Novel methods leading to new medications in depression and schizophrenia

IMIDIA: Improving beta-cell function and identification of diagnostic biomarkers for treatment monitoring in diabetes

PharmaTrain: Pharmaceutical and medicine training program

EUPATI: European patients' academy on therapeutic innovation

Health Technology Assessment (HTA)


EFPIA Japan member companies have a wealth of experience on the use of HTA in EU countries and the various issues resulting from such use. Based on this experience, EFPIA Japan proposes the five rules below as guidelines for developing and debating HTA in Japan.

1. Involve all stakeholders in meaningful discussions at all stages of the process (patients, healthcare professionals, industry parties)
2. Set priorities for the initial, trial period of HTA
3. Focus not solely on cost considerations but also on achieving better, outcomes
4. Ensure no negative impact on patient access or physicians' freedom to prescribe
5. Reward innovation and minimize the burden for both government and industry

HTA may delay and obstruct access to innovative treatments

In Japan, there is a comparatively short time period between the regulatory approval of new treatments and the availability of national health insurance reimbursement, with reimbursement available within 60 to 90 days of approval. This provides citizens with access to a wide range of pharmaceuticals. Considering the introduction of cost-benefit evaluations should involve through discussions and investigations on consistency with existing pharmaceutical pricing rules, feasibility with regard to issues such as corporate structures and systems and any potential negative influence on patient access to innovative drugs.

Europe: Patients "W.A.I.T." indicator




Source: EFPIA annual survey 2010 & 2013.

Note: In the UK and Germany, insurance reimbursement is available from the day of marketing approval, but de facto delays are apparent as a result of HTA (such delays are not covered by this W.A.I.T. analysis).

Pharmaceutical Industry – Global Figures

BREAKDOWN OF THE WORLD PHARMACEUTICAL MARKET -2011 SALES


The European market is the second largest after the USA.
(Japan ranks second when taking individual countries into account.)



Note: Europe includes non-EU members and CIS markets
Source: EFPIA Data (Facts & Figures)

HEALTHCARE SPENDING AS A PERCENTAGE OF GDP IN OECD MEMBER NATIONS (2012 or latest available year)


Overwhelmingly high in the USA Around 10% in many European countries.



Source: OECD Factbook 2014

PHARMACEUTICAL R&D EXPENDITURE IN EUROPE, USA AND JAPAN (MILLION OF NATIONAL CURRENCY UNITS*), 1990-2011


The amount of investment in R&D for new drug creation in Japan is smaller and the growth rate is lower compared to Europe and the USA.



*Note: Europe: € million; USA \$ million; Japan ¥ million × 100
Source: EFPIA Data (Facts & Figures with additional information)

EMPLOYMENT IN THE PHARMACEUTICAL INDUSTRY (1990-2012)

The pharmaceutical industry provides stable employment in the European market.




Note: Data includes Croatia and Lithuania (since 2010), Estonia and Hungary (since 2009), Czech Republic (since 2008), Cyprus (since 2007), Romania & Slovakia (since 2005), Malta, Poland and Slovenia (since 2004)

Source: EFPIA Data (Facts & Figures)


Pharmaceutical Industry – Japan Figures

EFPIA Member Companies in Japan Sales (2014)



Source: IMS Japan Pharmaceutical Market
Data period: 2014 Dec. MAT ©2014 IMS Health
■ EFPIA-J sales: EFPIA Japan figures

The Number of approved New Drugs* (2012 – 2014)



Source: EFPIA Japan figures are based on data provided by the
*The Central Social Insurance Medical Council.


Employment in EFPIA Japan (2014)

Approximately 33,600 people are employed by 24 EFPIA Japan member companies.




Source: EFPIA Japan Secretariat Data

The pace of drug development in Japan is accelerating



†: Some projects were initiated prior to request for unapproved drugs Source: EFPIA Japan survey (data from 15 companies)

Sales revenue to R&D expense ratio in Japanese manufacturing industries (2013)



Source: Ministry of Internal Affairs and Communications
(Survey of Research and Development)

Total pharmaceutical market likely to be broadly flat over next 10 years *2

Average annual growth of just 0.13% expected



*1 Long-Listed Products, LLP (a) is the LLP whose Gx was launched before 2013, LLP (b) is the other LLP

*2 Consumption tax rate was fixed at 5% through the forecast period

Source: The result from EFPIA-J and IMS joint simulation project

EFPIA Japan Secretariat Office

c/o Bayer Yakuhin, Ltd.

Marunouchi Kitaguchi Bldg. 6-5, Marunouchi 1-chome, Chiyoda-ku, Tokyo 100-8265, Japan

TEL: 03-6301-3066 FAX: 03-6301-3060 E-mail: info@efpia.jp

URL: <http://www.efpia.jp/English/index-e.html>

(Created in January 2016)